Terns Pharmaceuticals Inc (NASDAQ:TERN)’s traded shares stood at 0.71 million during the latest session, with the company’s beta value hitting -0.49. At the last check today, the stock’s price was $10.20, to imply a decrease of -4.48% or -$0.48 in intraday trading. The TERN share’s 52-week high remains $11.40, putting it -11.76% down since that peak but still an impressive 68.04% since price per share fell to its 52-week low of $3.26. The company has a valuation of $717.90M, with an average of 4.67 million shares in intraday trading volume over the past 10 days and average of 1.81 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Terns Pharmaceuticals Inc (TERN), translating to a mean rating of 1.29. Of 5 analyst(s) looking at the stock, 0 analyst(s) give TERN a Sell rating. 0 of those analysts rate the stock as Overweight while 2 advise Hold as 3 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.34.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Terns Pharmaceuticals Inc (NASDAQ:TERN) trade information
After registering a -4.48% downside in the latest session, Terns Pharmaceuticals Inc (TERN) has traded red over the past five days. The 5-day price performance for the stock is 36.75%, and 51.81% over 30 days. With these gigs, the year-to-date price performance is 57.19%. Short interest in Terns Pharmaceuticals Inc (NASDAQ:TERN) saw shorts transact 1.8 million shares and set a 1.68 days time to cover.
The extremes give us $7 and $19 for target low and target high price respectively. As such, TERN has been trading -86.27% off suggested target high and 31.37% from its likely low.
Terns Pharmaceuticals Inc (TERN) estimates and forecasts
Looking at statistics comparing Terns Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Terns Pharmaceuticals Inc (TERN) shares are 44.09% up over the last 6 months, with its year-to-date growth rate lower than industry average at -3.15% against 17.50%. Revenue is forecast to grow 19.00% this quarter before falling -17.20% for the next one.
TERN Dividends
Terns Pharmaceuticals Inc has its next earnings report out on 2024-Nov-12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Terns Pharmaceuticals Inc (NASDAQ:TERN)’s Major holders
Terns Pharmaceuticals Inc insiders hold 1.50% of total outstanding shares, with institutional holders owning 101.23% of the shares at 102.77% float percentage. In total, 101.23% institutions holds shares in the company, led by ORBIMED ADVISORS LLC. As of 2024-06-30, the company held over 7.62 million shares (or 10.2326% of shares), all amounting to roughly $51.89 million.
The next major institution holding the largest number of shares is VIVO CAPITAL, LLC with 6.18 million shares, or about 8.3038% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $42.11 million.
We also have Fidelity Small Cap Growth Fund and iShares Russell 2000 ETF as the top two Mutual Funds with the largest holdings of the Terns Pharmaceuticals Inc (TERN) shares. Going by data provided on Jun 30, 2024, Fidelity Small Cap Growth Fund holds roughly 1.97 shares. This is just over 3.04% of the total shares, with a market valuation of $20.47 million. Data from the same date shows that the other fund manager holds a little less at 1.59, or 2.46% of the shares, all valued at about 16.54 million.
